121 related articles for article (PubMed ID: 20837356)
1. Predictive factors for prolonged survival in recurrent endometrial carcinoma: Implications for follow-up protocol.
Otsuka I; Uno M; Wakabayashi A; Kameda S; Udagawa H; Kubota T
Gynecol Oncol; 2010 Dec; 119(3):506-10. PubMed ID: 20837356
[TBL] [Abstract][Full Text] [Related]
2. CA 125 normalization with chemotherapy is independently predictive of survival in advanced endometrial cancer.
Hoskins PJ; Le N; Correa R
Gynecol Oncol; 2011 Jan; 120(1):52-5. PubMed ID: 20947152
[TBL] [Abstract][Full Text] [Related]
3. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer.
Gadducci A; Cosio S; Fanucchi A; Cristofani R; Genazzani AR
Anticancer Res; 2000; 20(3B):1977-84. PubMed ID: 10928137
[TBL] [Abstract][Full Text] [Related]
4. The long-term survival of women with surgical stage II endometrioid type endometrial cancer.
Ayhan A; Taskiran C; Celik C; Yuce K
Gynecol Oncol; 2004 Apr; 93(1):9-13. PubMed ID: 15047207
[TBL] [Abstract][Full Text] [Related]
5. Use of preoperative serum CA-125 levels for prediction of lymph node metastasis and prognosis in endometrial cancer.
Chung HH; Kim JW; Park NH; Song YS; Kang SB; Lee HP
Acta Obstet Gynecol Scand; 2006; 85(12):1501-5. PubMed ID: 17260229
[TBL] [Abstract][Full Text] [Related]
6. Lymphovascular invasion is a significant predictor for distant recurrence in patients with early-stage endometrial endometrioid adenocarcinoma.
Nofech-Mozes S; Ackerman I; Ghorab Z; Ismiil N; Thomas G; Covens A; Khalifa MA
Am J Clin Pathol; 2008 Jun; 129(6):912-7. PubMed ID: 18480008
[TBL] [Abstract][Full Text] [Related]
7. Stage I, grade 3 endometrioid adenocarcinoma of the endometrium: an analysis of clinical outcomes and patterns of recurrence.
Rasool N; Fader AN; Seamon L; Neubauer NL; Shahin FA; Alexander HA; Moore K; Moxley K; Secord AA; Kunos C; Rose PG; O'Malley DM
Gynecol Oncol; 2010 Jan; 116(1):10-4. PubMed ID: 19875158
[TBL] [Abstract][Full Text] [Related]
8. [Synchronous primary cancers of the endometrium and ovary: review of 43 cases].
Ma SK; Zhang HT; Sun YC; Wu LY
Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):690-4. PubMed ID: 19173912
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of serum CA-125 levels for preoperative counseling in endometrioid endometrial cancer: a multi-center study.
Kim HS; Park CY; Lee JM; Lee JK; Cho CH; Kim SM; Kim JW
Gynecol Oncol; 2010 Sep; 118(3):283-8. PubMed ID: 20541245
[TBL] [Abstract][Full Text] [Related]
10. Measurement of the minimum apparent diffusion coefficient (ADCmin) of the primary tumor and CA125 are predictive of disease recurrence for patients with endometrial cancer.
Nakamura K; Imafuku N; Nishida T; Niwa I; Joja I; Hongo A; Kodama J; Hiramatsu Y
Gynecol Oncol; 2012 Feb; 124(2):335-9. PubMed ID: 22008707
[TBL] [Abstract][Full Text] [Related]
11. Letter to the editor in response to "Stage 1, grade 3 endometrioid adenocarcinoma of the endometrium: An analysis of clinical outcomes and patterns of recurrence".
Pollock J
Gynecol Oncol; 2010 Jun; 117(3):507; author reply 507-8. PubMed ID: 20189231
[No Abstract] [Full Text] [Related]
12. Misleading CA-125 levels and computed tomography images in an endometrial cancer patient.
Tjalma WA
J Obstet Gynaecol; 2004 Jun; 24(4):470-1. PubMed ID: 15203605
[No Abstract] [Full Text] [Related]
13. Endometrial giant cell carcinoma: a case series and review of the spectrum of endometrial neoplasms containing giant cells.
Mulligan AM; Plotkin A; Rouzbahman M; Soslow RA; Gilks CB; Clarke BA
Am J Surg Pathol; 2010 Aug; 34(8):1132-8. PubMed ID: 20588176
[TBL] [Abstract][Full Text] [Related]
14. DNA ploidy is an independent prognostic indicator of overall survival in stage I endometrial endometrioid carcinoma.
Santala M; Talvensaari-Mattila A
Anticancer Res; 2003; 23(6D):5191-6. PubMed ID: 14981988
[TBL] [Abstract][Full Text] [Related]
15. [Multivariate analysis of prognostic factors in endometrial carcinoma].
Li B; Wu LY; Li SM; Zhang WH; Zhang R; Ma SK
Ai Zheng; 2004 Sep; 23(9):1085-8. PubMed ID: 15363208
[TBL] [Abstract][Full Text] [Related]
16. FIGO stage IIIC endometrial carcinoma: prognostic factors and outcomes.
Hoekstra AV; Kim RJ; Small W; Rademaker AW; Helenowski IB; Singh DK; Schink JC; Lurain JR
Gynecol Oncol; 2009 Aug; 114(2):273-8. PubMed ID: 19428094
[TBL] [Abstract][Full Text] [Related]
17. Treatment of pulmonary recurrences in patients with endometrial cancer.
Dowdy SC; Mariani A; Bakkum JN; Cliby WA; Keeney GL; Podratz KC
Gynecol Oncol; 2007 Nov; 107(2):242-7. PubMed ID: 17869330
[TBL] [Abstract][Full Text] [Related]
18. Value of circulating tumor cells positive for thyroid transcription factor-1 (TTF-1) to predict recurrence and survival rates for endometrial carcinoma.
Zhang Y; Qu X; Qu PP
J BUON; 2016; 21(6):1491-1495. PubMed ID: 28039713
[TBL] [Abstract][Full Text] [Related]
19. Serial serum CA 125 measurements for evaluation of recurrence in patients with endometrial carcinoma.
Rose PG; Sommers RM; Reale FR; Hunter RE; Fournier L; Nelson BE
Obstet Gynecol; 1994 Jul; 84(1):12-6. PubMed ID: 8008305
[TBL] [Abstract][Full Text] [Related]
20. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer.
Alektiar KM; Venkatraman E; Chi DS; Barakat RR
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):111-7. PubMed ID: 15850910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
